Sequential treatment with biologics: Switching from efalizumab to etanercept in 35 patients with high-need psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 12, 2010, Pages 1413-1420

  Antoniou, C ^a   Dessinioti, C ^a   Vergou, T ^a   Stratigos, A J ^a   Avgerinou, G ^a   Kostaki, M ^b   Katsambas, A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

biologics; combination therapy; efalizumab; etanercept; psoriasis; switching

Indexed keywords

CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; METHOTREXATE;

ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; BALANITIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; LARGE CELL LYMPHOMA; LIPIDOSIS; LOWER RESPIRATORY TRACT INFECTION; MALE; MONOTHERAPY; MOUTH CARCINOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PSORIASIS VULGARIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VERRUCA VULGARIS;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES;

EID: 78449313936     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03661.x     Document Type: Article

References (57)

1. Gaspari AA,. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006; 54: S67-S80.
2. Torti DC, Feldman SR,. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007; 57: 1059-1068.
3. Aggarwal S, Ghilardi N, Xie MH, De Sauvage FJ, Gurney AL,. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-1914.
4. Teunissen MB, Koomen CW, De Waal Malefyt R, Wierenga EA, Bos JD,. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111: 645-649.
5. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
6. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunology 2005; 175: 2721-2729.
7. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632.
8. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
9. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet 2006; 367: 29-35.
10. Jacob SE, Sergay A, Kerdel FA,. Etanercept and psoriasis, from clinical studies to real life. Int J Dermatol 2005; 44: 688-691.
11. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726.
12. Ahmad K, Rogers S,. Two years of experience with etanercept in recalcitrant psoriasis. Br J Dermatol 2007; 156: 1010-1014.
13. De Groot M, Appelman M, Spuls PI, De Rie MA, Bos JD,. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 2006; 155: 808-814.
14. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007; 56: 598-603.
15. Gordon KB, Gottlieb AB, Leonardi CL, et al. Clinical response in psoriasis patients discontinued form and then reinitiated on etanercept therapy. J Dermatolog Treat 2006; 17: 9-17.
16. Antoniou C, Dessinioti C, Stratigos AJ, Avgerinou G, Stavropoulos P, Katsambas A,. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience. J Eur Acad Dermatol Venereol 2009; 23: 979-982.
17. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescent with plaque psoriasis. N Engl J Med 2008; 358: 241-251.
18. Driessen RJB, Berends MAM, Boezeman JB, Van De Kerkhof PC, De Jong EM,. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome. Br J Dermatol 2008; 158: 1098-1106.
19. Griffiths CE, Strober BE, Van De Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-128.
20. Thielen AM, Kuenzli S, Saurat JH,. Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 2005; 211: 207-215.
21. Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-497.
22. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. J Am Acad Dermatol 2008; 58: 851-864.
23. Antoniou C, Dessinioti C, Katsambas A, Stratigos AJ,. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-α therapy in a patient with psoriatic arthritis and psoriasis vulgatis. Br J Dermatol 2007; 156: 1090-1091.
24. Leonardi C,. Efalizumab in the treatment of psoriasis. Dermatol Ther 2004; 17: 393-400.
25. Menter A, Hamilton TK, Toth DP, et al. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. Int J Dermatol 2007; 46: 637-648.
26. Van Riel PL, Taggart AJ, Sany J, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006; 65: 1478-1483.
27. Van der Heijde D, Klareskog I, Rodriguezs-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arhtritis Rheum 2006; 54: 1063-1064.
28. Klareskog L, Van Der Heijde D, De Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004; 363: 675-681.
29. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-259.
30. Zhou H, Mayer PR, Wajdula J, Fatenejad S,. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 2004; 44: 1235-1243.
31. Driessen RJB, Van de Kerkhof PCM, De Jong EMGJ,. Etanercept combined with methotrexate for high-need psoriasis. Br J Dermatol 2008; 159: 460-463.
32. Warren RB, Brown BC, Lavery D, Ashcroft DM, Griffiths CE,. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol 2009; 160: 162-169.
33. Yamauchi PS, Lowe NS, Koo S,. Etanercept therapy allows tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis. Presented at the American Academy of Dermatology, February 18-22 2005, New Orleans, Louisiana. Abstract P2754
34. Chan ES, Cronstein BN,. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002; 4: 266-273.
35. Kragballe K, Jansen CT, Geiger JM, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicenter study. Acta Derm Venereol (Stockh) 1989; 69: 35-40.
36. Gisondi P, Del Giglio M, Cotena C, Girolomoni G,. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008; 158: 1345-1349.
37. Hodulik SG, Zeichner JA,. Combination therapy with acitretin for psoriasis. J Dermatol Treat 2006; 1: 108-111.
38. Iannone F, Trotta F, Montecucco C, et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab due to side effects. Ann Rheum Dis 2007; 66: 249-252.
39. Gomez-Reino JJ, Carmona L,. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthr Res Ther 2006; 8: R29.
40. Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B,. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 795-800. (Pubitemid 43040507)
41. Van Vollenhoven RF,. Switching between biological agents. Clin Exp Rheumatol 2004; 22 (suppl): s115-s121.
42. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ,; British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis. Arthr Rheum 2007; 56: 13-20.
43. Lecluse LLA, De Groot M, Bos JD, Spuls PI,. Experience with biologics for psoriasis in daily practice: switching is worth a try. Br J Dermatol 2009; 161: 948-951.
44. Martyn-Simmons CL, Green L, Ash G, Groves RW, Smith CH, Barker JN,. Adalimumab for psoriasis patietns who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol 2009; 23: 1394-1397.
45. Van L, Modi SV, Yang DJ, Hsu S,. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-α antagonist treatment. Arch Dermatol 2008; 144: 804-806.
46. Barde C, Thielen AM, Kuenzli S, Saurat JH,. Treatment of plaque psoriasis by sequential therapy with two 'biologics': the 'hit and run' approach, a report of two cases. Br J Dermatol 2006; 155: 207-229.
47. Haitz KA, Kalb RE,. Infliximab in the treatment of psoriasis in patients previously treated with etanercept. J Am Acad Dermatol 2007; 57: 120-125.
48. Pitarch G, Sanchez-Carazo JL, Mahiques L, Oliver V,. Efficacy of etanercept in psoriatic patients previously treated with infliximab. Dermatology 2008; 216: 312-316.
49. Papoutsaki M, Chimenti MS, Constanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57: 269-275.
50. Yamauchi PS, Mau N,. Adalimumab treats psoriasis in patients previously treated with etanercept: a case series. J Am Acad Dermatol 2009; 61: 158-160.
51. Mazotta A, Esposito M, Constanzo A, Chimenti S,. Efficacy and safety of etanercept in psoriasis after switching from other treatments. Am J Clin Dermatol 2009; 10: 319-324.
52. Van Vollenhoven R, Harju A, Brannemark S, Klareskog L,. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumor necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003; 62: 1195-1198.
53. Ang HT, Helfgott S,. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003; 30: 2315-2318.
54. Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 1098-1102.
55. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D,. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005; 52: 2693-2696.
56. Stefanaki I, Dimisianos G, Antoniou C, Katsambas A, Stratigos A,. Investigation of +405 and -460 polymorphisms of vascular endothelial growth factor in psoriasis and short-term responsiveness to efalizumab therapy. Dermatology 2008; 217: 201-202.
57. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naïve patients: a cohort study. Ann Rheum Dis 2009. epub ahead of print